At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 25, 2026 at 17:08 ET
Spero Therapeutics filed an 8-K reporting shareholder approval to double authorized common shares from 120M to 240M and adopt a new 2026 Stock Incentive Plan authorizing up to 12.9M shares. These are routine post-annual-meeting governance actions with no immediate financial impact or operational changes.
- Shareholders approved amendment to increase authorized common shares from 120,000,000 to 240,000,000.
- Shareholders approved the 2026 Stock Incentive Plan, authorizing up to 12,895,866 shares for issuance.
- Annual meeting held June 23, 2026; quorum of 70.91% of outstanding shares present.
- Directors Milind Deshpande and Kathleen Tregoning were reelected as Class III directors.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access